A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of an alternative dose of
ramucirumab in combination with paclitaxel in participants with second-line metastatic or
locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma (GEJ).